GoodRx Holdings Analyst Price Targets - Benzinga

SPY778.57+0.60%QQQ751.38+0.51%BTC/USD82,976.95+0.50%DIA516.21+0.89%GLD384.50+1.55%TLT77.97+0.12%

GoodRx Holdings Inc

GDRXNASDAQ

Trade with Public

Trade with Public

$3.43

0.072.08%

Last update: Oct 9, 6:11 PM

Overview News Earnings Forecast EventsPrice TargetsFinancials Sentiment Ownership Compare Options Stock Report

Connect With Us

About Benzinga

Market Resources

Trading Tools & Education

Ring the Bell

© 2026 Benzinga | All Rights Reserved

GoodRx Holdings Analyst Price Targets - Benzinga

GoodRx Holdings Analyst Price Targets

Wall Street analyst price targets and consensus rating for GoodRx Holdings (GDRX).

Price Target Range — 12 Quarters

Analyst Consensus — 15 Analysts

7Buy

6Hold

2Sell

Consensus RatingOutperform# Analysts15Avg. Consensus PT$6Upside to Avg. PT+68.5%

Rating Trend — Last 9 Months

Recent Analyst Actions

See all ratings →

Date	Firm	Analyst	Action	Rating Change	Price Target
Aug 21, 2026	Barclays	Glen Santangelo	PT Raise	Underweight	$3→$4
Aug 13, 2026	UBS	Kevin Caliendo	PT Raise	Neutral	$3→$4
Aug 11, 2026	Citigroup	Daniel Grosslight	PT Raise	Buy	$4→$5
Aug 11, 2026	TD Cowen	Charles Rhyee	PT Raise	Buy	$4→$5
Aug 7, 2026	Wells Fargo	Stan Berenshteyn	PT Raise	Overweight	$4→$5
May 14, 2026	Citigroup	Daniel Grosslight	PT Raise	Buy	$4→$4
May 11, 2026	TD Cowen	Charles Rhyee	PT Raise	Buy	$3→$4
Mar 4, 2026	Wells Fargo	Stan Berenshteyn	PT Cut	Overweight	$7→$4
Mar 3, 2026	Citigroup	Daniel Grosslight	PT Cut	Buy	$5→$4
Mar 2, 2026	Goldman Sachs	Eric Sheridan	PT Cut	Neutral	$4→$3
Feb 27, 2026	Mizuho	Steven Valiquette	PT Cut	Neutral	$4→$3
Feb 27, 2026	JP Morgan	Lisa Gill	Downgrade	Overweight→Neutral	—
Jan 22, 2026	Jefferies	Glen Santangelo	Downgrade	Buy→Hold	$5→$3
Jan 9, 2026	Citigroup	Daniel Grosslight	PT Cut	Buy	$5→$5
Dec 18, 2025	Morgan Stanley	Craig Hettenbach	PT Cut	Equal-Weight	$5→$4
Dec 9, 2025	Barclays	Glen Santangelo	Initiate	Underweight	$3
Nov 11, 2025	JP Morgan	Lisa Gill	PT Cut	Overweight	$6→$5
Nov 10, 2025	TD Cowen	Charles Rhyee	PT Cut	Buy	$7→$6
Nov 6, 2025	UBS	Kevin Caliendo	PT Cut	Neutral	$4→$4
Nov 6, 2025	Mizuho	Steven Valiquette	PT Cut	Neutral	$5→$4

More with Benzinga EdgeGet Access

Analyst Ratings News

PRO
Barclays Maintains Underweight on GoodRx Holdings, Raises Price Target to $4

Barclays analyst Glen Santangelo maintains GoodRx Holdings (NASDAQ:GDRX) with a Underweight and raises the price target from $3 to $4.

Benzinga Newsdesk

PRO
UBS Maintains Neutral on GoodRx Holdings, Raises Price Target to $3.75

UBS analyst Kevin Caliendo maintains GoodRx Holdings (NASDAQ:GDRX) with a Neutral and raises the price target from $2.5 to $3.75.

Benzinga Newsdesk

PRO
Citigroup Maintains Buy on GoodRx Holdings, Raises Price Target to $5

Citigroup analyst Daniel Grosslight maintains GoodRx Holdings (NASDAQ:GDRX) with a Buy and raises the price target from $4 to $5.

Benzinga Newsdesk

PRO
TD Cowen Maintains Buy on GoodRx Holdings, Raises Price Target to $5

TD Cowen analyst Charles Rhyee maintains GoodRx Holdings (NASDAQ:GDRX) with a Buy and raises the price target from $4 to $5.

Benzinga Newsdesk

PRO
Citigroup Maintains Buy on GoodRx Holdings, Raises Price Target to $4

Citigroup analyst Daniel Grosslight maintains GoodRx Holdings (NASDAQ:GDRX) with a Buy and raises the price target from $3.5 to $4.

Benzinga Newsdesk

PRO
TD Cowen Maintains Buy on GoodRx Holdings, Raises Price Target to $4

TD Cowen analyst Charles Rhyee maintains GoodRx Holdings (NASDAQ:GDRX) with a Buy and raises the price target from $3 to $4.

Benzinga Newsdesk